N4 Pharma
Clinical-stage biotechnology company focused on RNA therapeutics and RNA delivery technologies for oncology and cardiovascular disease. The company develops microRNA- and siRNA-based therapeutic candidates, conducts preclinical and IND-enabling studies with external partners, and sponsors a Phase 1 dose‑escalation clinical trial in acute myeloid leukaemia. The transition to clinical stage followed an acquisition that added a Phase 1 microRNA therapeutic to the pipeline and was supported by a recent fundraise.
Industries
Nr. of Employees
small (1-50)
Products
Clinical-stage microRNA inhibitor for acute myeloid leukaemia
A clinical-stage microRNA inhibitor designed to modulate a microRNA implicated in leukaemia stem cell survival; currently subject to Phase 1 dose-escalation clinical evaluation for relapsed or refractory acute myeloid leukaemia.
Preclinical bispecific siRNA for cardiovascular risk reduction
A preclinical bispecific siRNA candidate designed for simultaneous silencing of two cardiovascular risk drivers as a long-duration dosing approach to reduce cardiovascular risk.
Particle-based RNA delivery platform
A particle-based delivery technology designed for multi-RNA loading, flexible targeting and scalable formulation; characterised using ex‑vivo payload release assays and liver-targeting approaches.
Additional preclinical RNA candidates progressing toward IND
Multiple preclinical nucleic-acid therapeutic candidates advancing through preclinical studies with target IND submission timelines provided by company communications (targeting H2 2027 for selected assets).
N4 101
N4 101 is an oral capsule containing dual-loaded nucleic acids in pre-clinical development as an orally delivered inflammation inhibitor for inflammatory bowel disease using Nuvec silica nanoparticles.
Nuvec
A next-generation spiky silica nanoparticle gene delivery platform engineered to overcome key challenges of RNA delivery, including protection, stability, and effective cell uptake.
Clinical-stage microRNA inhibitor for acute myeloid leukaemia
A clinical-stage microRNA inhibitor designed to modulate a microRNA implicated in leukaemia stem cell survival; currently subject to Phase 1 dose-escalation clinical evaluation for relapsed or refractory acute myeloid leukaemia.
Preclinical bispecific siRNA for cardiovascular risk reduction
A preclinical bispecific siRNA candidate designed for simultaneous silencing of two cardiovascular risk drivers as a long-duration dosing approach to reduce cardiovascular risk.
Particle-based RNA delivery platform
A particle-based delivery technology designed for multi-RNA loading, flexible targeting and scalable formulation; characterised using ex‑vivo payload release assays and liver-targeting approaches.
Additional preclinical RNA candidates progressing toward IND
Multiple preclinical nucleic-acid therapeutic candidates advancing through preclinical studies with target IND submission timelines provided by company communications (targeting H2 2027 for selected assets).
N4 101
N4 101 is an oral capsule containing dual-loaded nucleic acids in pre-clinical development as an orally delivered inflammation inhibitor for inflammatory bowel disease using Nuvec silica nanoparticles.
Nuvec
A next-generation spiky silica nanoparticle gene delivery platform engineered to overcome key challenges of RNA delivery, including protection, stability, and effective cell uptake.
Services
Outsourced synthesis, in vitro and in vivo testing, and ex‑vivo delivery characterisation executed with contract research organisations and academic centres to progress candidates toward IND-enabling studies.
Sponsor-led oversight of early‑phase clinical trials including dose-escalation design, cohort management and generation of interim and topline clinical data to support regulatory progression.
Outsourced synthesis, in vitro and in vivo testing, and ex‑vivo delivery characterisation executed with contract research organisations and academic centres to progress candidates toward IND-enabling studies.
Sponsor-led oversight of early‑phase clinical trials including dose-escalation design, cohort management and generation of interim and topline clinical data to support regulatory progression.
Expertise Areas
- RNA therapeutics development
- microRNA-targeted therapeutics
- siRNA and bispecific siRNA programmes
- Particle-based RNA delivery platform development
Key Technologies
- microRNA inhibition modalities
- bispecific and multi-target siRNA
- non-viral nanoparticle delivery platforms
- GalNAc-mediated liver targeting approaches
News & Updates
Shareholder-approved acquisition completed; issuance of new ordinary shares and a convertible loan note were reported and admission to AIM followed.
Update included ongoing Phase 1 trial for a microRNA therapeutic, commencement of preclinical work with a CRO for a bispecific siRNA, and ex‑vivo liver targeting studies for the delivery platform.
Announcement reporting total voting rights and post-admission share capital following admission.
External analyst report providing independent analysis of the company's strategy and prospects.
Interview with the company's CEO discussing the acquisition that moved the company to clinical stage and strategic priorities.
Webcast outlining the strategic rationale for the acquisition, details of the Phase 1 programme, and milestones to watch; confirmed funding to support clinical work and pipeline through mid-2027.
Shareholder-approved acquisition completed; issuance of new ordinary shares and a convertible loan note were reported and admission to AIM followed.
Update included ongoing Phase 1 trial for a microRNA therapeutic, commencement of preclinical work with a CRO for a bispecific siRNA, and ex‑vivo liver targeting studies for the delivery platform.
Announcement reporting total voting rights and post-admission share capital following admission.
External analyst report providing independent analysis of the company's strategy and prospects.
Interview with the company's CEO discussing the acquisition that moved the company to clinical stage and strategic priorities.
Webcast outlining the strategic rationale for the acquisition, details of the Phase 1 programme, and milestones to watch; confirmed funding to support clinical work and pipeline through mid-2027.